Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GenFleet’s KRAS G12C Inhibitor Approved for NSCLC in China

publication date: Aug 23, 2024

GenFleet Therapeutics was approved for a China launch of Dupert (fulzerasib),a KRAS G12C inhibitor, as a second-line treatment for advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation. Patients must have previously had at least one systemic therapy. About 85% of all lung cancers are NSCLC, and KRAS is the most frequently mutated driver gene in NSCLC. The approve is a first in China for a KRAS G12C inhibitor. In 2021, GenFleet out-licensed greater China commercialization rights for fulzerasib to Suzhou’s Innovent in a deal worth up to $315 million. More details...

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here